1 |
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones[J]. J Hepatol, 2016, 65(1): 146-181.
|
2 |
中华消化杂志编辑委员会, 中华医学会消化病学分会肝胆疾病协作组. 中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年)[J]. 中华消化杂志, 2019, 39(2): 73-79.
|
3 |
Shabanzadeh DM, Sørensen LT, Jørgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study[J]. Gastroenterology, 2016, 150(1): 156-167.e1.
|
4 |
Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation: a new data cohort study and a systematic review with meta-analysis[J]. Scand J Gastroenterol, 2016, 51(10): 1239-1248.
|
5 |
王启晗, 张中文, 吴健, 等. 上海地区胆囊结石病的流行病学调查[J]. 外科理论与实践, 2018, 23(3): 252-257.
|
6 |
朱颖, 吴治宇, 马向明, 等. 开滦集团职工胆囊结石临床流行病学调查[J]. 临床肝胆病杂志, 2015, 31(10): 1621-1624.
|
7 |
Wang HH, Portincasa P, Liu M, et al. An update on the lithogenic mechanisms of cholecystokinin a receptor (CCKAR), an important gallstone gene for Lith13[J]. Genes, 2020, 11(12): 1438.
|
8 |
Sieron D, Czerny B, Sieron-Stoltny K, et al. The effect of chronic estrogen application on bile and gallstone composition in women with cholelithiasis[J]. Minerva Endocrinol, 2016, 41(1): 19-27.
|
9 |
Simonsen MH, Erichsen R, Frøslev T, et al. Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study[J]. Drug Saf, 2013, 36(12): 1189-1197.
|
10 |
Murphy E. Estrogen signaling and cardiovascular disease[J]. Circ Res, 2011, 109(6): 687-696.
|
11 |
Lagranha CJ, Silva TLA, Silva SCA, et al. Protective effects of estrogen against cardiovascular disease mediated via oxidative stress in the brain[J]. Life Sci, 2018, 192: 190-198.
|
12 |
Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol, 2017, 1043: 227-256.
|
13 |
Handgraaf S, Philippe J. The role of sexual hormones on the enteroinsular axis[J]. Endocr Rev, 2019, 40(4): 1152-1162.
|
14 |
Mauvais-Jarvis F, Le May C, Tiano JP, et al. The role of estrogens in pancreatic islet physiopathology[J]. Adv Exp Med Biol, 2017, 1043: 385-399.
|
15 |
Farman HH, Gustafsson KL, Henning P, et al. Membrane estrogen receptor α is essential for estrogen signaling in the male skeleton[J]. J Endocrinol, 2018, 239(3): 303-312.
|
16 |
Morselli E, Santos RDS, Gao S, et al. Impact of estrogens and estrogen receptor-α in brain lipid metabolism[J]. Am J Physiol Endocrinol Metab, 2018, 315(1): E7-E14.
|
17 |
Jacenik D, Cygankiewicz AI, Fichna J, et al. Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome[J]. Mol Cell Endocrinol, 2018, 471: 89-96.
|
18 |
Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium[J]. Endocr Rev, 2018, 39(5): 664-675.
|
19 |
Barton M, Filardo EJ, Lolait SJ, et al. Twenty years of the G protein-coupled estrogen receptor GPER: historical and personal perspectives[J]. J Steroid Biochem Mol Biol, 2018, 176: 4-15.
|
20 |
Rebholz C, Krawczyk M, Lammert F. Genetics of gallstone disease[J]. Eur J Clin Invest, 2018, 48(7): e12935.
|
21 |
蒋兆彦, 胡海, 韩天权, 等. 胆固醇的肠肝循环: 肝脏和小肠在胆石形成中的作用[J]. 外科理论与实践, 2017, 22(3): 191-194.
|
22 |
Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease[J]. Curr Opin Gastroenterol, 2018, 34(2): 71-80.
|
23 |
Cortés VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity[J]. Obes Rev, 2020, 21(4): e12983.
|
24 |
Lammert F, Gurusamy K, Ko CW, et al. Gallstones[J]. Nat Rev Dis Primers, 2016, 2: 16024.
|
25 |
Wang HH, Afdhal NH, Wang DQH. Estrogen receptor α, but not β, plays a major role in 17β-estradiol-induced murine cholesterol gallstones[J]. Gastroenterology, 2004, 127(1): 239-249.
|
26 |
Saha P, Shumate JL, Caldwell JG, et al. Inter-domain dynamics drive cholesterol transport by NPC1 and NPC1L1 proteins[J]. Elife, 2020, 9: e57089.
|
27 |
Duan LP, Wang HH, Ohashi A, et al. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(2): G269-G276.
|
28 |
de Bari O, Wang HH, Portincasa P, et al. Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice[J]. Eur J Clin Invest, 2014, 44(12): 1159-1168.
|
29 |
Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13(12): 710-730.
|
30 |
Wang HH, Afdhal NH, Wang DQH. Overexpression of estrogen receptor α increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice[J]. J Lipid Res, 2006, 47(4): 778-786.
|
31 |
de Bari O, Wang HH, Portincasa P, et al. The deletion of the estrogen receptor α gene reduces susceptibility to estrogen-induced cholesterol cholelithiasis in female mice[J]. Biochim Biophys Acta, 2015, 1852(10Pt A): 2161-2169.
|
32 |
de Bari O, Wang TY, Liu M, et al. Estrogen induces two distinct cholesterol crystallization pathways by activating ERα and GPR30 in female mice[J]. J Lipid Res, 2015, 56(9): 1691-1700.
|
33 |
Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30[J]. Nat Chem Biol, 2006, 2(4): 207-212.
|
34 |
Wang HH, de Bari O, Arnatt CK, et al. Activation of estrogen receptor G protein-coupled receptor 30 enhances cholesterol cholelithogenesis in female mice[J]. Hepatol, 2020, 72(6): 2077-2089.
|
35 |
DeLeon C, Wang HH, Gunn J, et al. A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice[J]. J Lipid Res, 2020, 61(5): 767-777.
|